This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 21, 2007
Last updated: September 24, 2009
Last verified: September 2009

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Capecitabine may also make tumor cells more sensitive to radiation therapy. Giving radiation together with capecitabine after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving capecitabine together with radiation therapy works in treating patients with nonmetastatic breast cancer.

Condition Intervention Phase
Breast Cancer Drug: capecitabine Procedure: adjuvant therapy Radiation: radiation therapy Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Safety And Feasibility Study Of Concurrent Capecitabine (Xeloda) And External Beam Irradiation In The Adjuvant Treatment Of High Risk Early Stage Breast Cancer.

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Overall safety

Secondary Outcome Measures:
  • Cosmesis, skin toxicity and wound healing at 1 year
  • Recurrence at 1 year

Estimated Enrollment: 50
Study Start Date: September 2004
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Detailed Description:



  • To determine the safety and feasibility of concurrent capecitabine and standard external-beam irradiation in patients with high-risk early stage breast cancer.


  • To determine the effects of concurrent treatment on cosmesis and wound healing at 1 year.
  • To determine the short-term (1-year) risk of recurrence of breast cancer in these patients.

OUTLINE: This is a multicenter study.

Patients undergo external-beam radiotherapy once daily, 5 days a week and concurrently receive oral capecitabine twice daily, 5 days a week Monday through Friday, for approximately 6-7 weeks.

After completion of study therapy, patients are followed at approximately 1 week, 1 month, 6 months, and 12 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed invasive adenocarcinoma of the breast, meeting 1 of the following high-risk criteria:

    • T3 or T4 primary tumor
    • 4 or more involved axillary lymph nodes (N2 nodal stage)
  • Completed surgical excision

    • No immediate reconstruction with autologous flap reconstruction

      • Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion
  • No residual breast cancer

    • Microscopically positive margins are allowed if a re-excision is not felt to be clinically justified
  • Candidate for radiotherapy

    • Must not require bilateral radiotherapy
  • No metastatic (stage IV) breast cancer by AJCC staging criteria
  • Hormone receptor status not specified
  • No CNS disorders


  • Life expectancy ≥ 6 months
  • Karnofsky performance status 70-100%
  • Menopausal status not specified
  • Ambulatory
  • Hemoglobin > 9 g/dL
  • Platelet count > 100,000/mm³
  • ANC > 1,500/mm³
  • Serum AST, ALT, and alkaline phosphatase ≤ 2 times upper limit of normal (ULN)
  • Total bilirubin normal
  • Creatinine clearance > 50 mL/min
  • Negative pregnancy test
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during study and for 30 days after the last study drug administration
  • No serious, uncontrolled, concurrent infection(s)
  • No diabetes with current or history of delayed wound healing or skin ulcers
  • No autoimmune connective tissue disorder
  • No prior unanticipated severe reaction to fluoropyrimidine therapy, known sensitivity to 5-fluorouracil, or known dihydropyrimidine dehydrogenase (DPD) deficiency
  • No other carcinomas within the last five years except cured non-melanoma skin cancer and in-situ cervical cancer
  • No clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months
  • No other serious uncontrolled medical conditions that the investigator feels might compromise study participation, including any of the following:

    • Uncontrolled seizures
    • Psychiatric disability judged by the investigator to be clinically significant
  • Physically intact upper gastrointestinal tract
  • No malabsorption syndrome
  • No uncompensated coagulopathy
  • No patients whose breast size or body contour puts them at increased risk for skin desquamation from standard radiotherapy
  • Able to read and speak English


  • Fully recovered from surgery and chemotherapy with completely healed surgical wounds
  • At least 4 weeks since completion of prior chemotherapy regimen, excluding trastuzumab (Herceptin®)

    • Concurrent trastuzumab allowed at the physician's discretion
  • More than 4 weeks since prior participation in any investigational drug study
  • At least 4 weeks since prior and no concurrent sorivudine or brivudine
  • More than 2 weeks since prior major surgery
  • No prior capecitabine
  • No prior radiotherapy to the chest or ipsilateral lymphatics
  • No concurrent hormonal therapy during course of chemotherapy or radiation therapy
  • No concurrent allopurinol or cimetidine
  • Concurrent coumadin is allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00562718

United States, Texas
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Simmons Cancer Center
Study Chair: Dan P. Garwood, MD Simmons Cancer Center
  More Information

Responsible Party: Dan P. Garwood, Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Identifier: NCT00562718     History of Changes
Other Study ID Numbers: CDR0000574761
Study First Received: November 21, 2007
Last Updated: September 24, 2009

Keywords provided by National Cancer Institute (NCI):
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
male breast cancer
recurrent breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on August 16, 2017